Unknown

Dataset Information

0

Novel Chiral Ru(II) Complexes as Potential c-myc G-quadruplex DNA Stabilizers Inducing DNA Damage to Suppress Triple-Negative Breast Cancer Progression.


ABSTRACT: Currently, effective drugs for triple-negative breast cancer (TNBC) are lacking in clinics. c-myc is one of the core members during TNBC tumorigenesis, and G-rich sequences in the promoter region can form a G-quadruplex conformation, indicating that the c-myc inhibitor is a possible strategy to fight cancer. Herein, a series of chiral ruthenium(II) complexes ([Ru(bpy)2(DPPZ-R)](ClO4)2, Λ/Δ-1: R = -H, Λ/Δ-2: R = -Br, Λ/Δ-3: R = -C≡C(C6H4)NH2) were researched based on their interaction with c-myc G-quadruplex DNA. Λ-3 and Δ-3 show high affinity and stability to decrease their replication. Additional studies showed that Λ-3 and Δ-3 exhibit higher inhibition against different tumor cells than other molecules. Δ-3 decreases the viability of MDA-MB-231 cells with an IC50 of 25.51 μM, which is comparable with that of cisplatin, with an IC50 of 25.9 μM. Moreover, Δ-3 exhibits acceptable cytotoxic activity against MDA-MB-231 cells in a zebrafish xenograft breast cancer model. Further studies suggested that Δ-3 decreases the viability of MDA-MB-231 cells predominantly through DNA-damage-mediated apoptosis, which may be because Δ-3 can induce DNA damage. In summary, the results indicate that Ru(II) complexes containing alkinyl groups can be developed as c-myc G-quadruplex DNA binders to block TNBC progression.

SUBMITTER: Yuan C 

PROVIDER: S-EPMC9820592 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel Chiral Ru(II) Complexes as Potential c-myc G-quadruplex DNA Stabilizers Inducing DNA Damage to Suppress Triple-Negative Breast Cancer Progression.

Yuan Chanling C   Wang Zhixiang Z   Wang Zongtao Z   Liu Wentao W   Li Guohu G   Meng Jinlan J   Wu Ruzhen R   Wu Qiong Q   Wang Jiacheng J   Mei Wenjie W  

International journal of molecular sciences 20221222 1


Currently, effective drugs for triple-negative breast cancer (TNBC) are lacking in clinics. c-myc is one of the core members during TNBC tumorigenesis, and G-rich sequences in the promoter region can form a G-quadruplex conformation, indicating that the c-myc inhibitor is a possible strategy to fight cancer. Herein, a series of chiral ruthenium(II) complexes ([Ru(bpy)<sub>2</sub>(DPPZ-R)](ClO<sub>4</sub>)<sub>2</sub>, <b><i>Λ/</i><i>Δ</i></b>-1: R = -H, <b><i>Λ/</i><i>Δ</i></b>-2: R = -Br, <b><i  ...[more]

Similar Datasets

| S-EPMC2553577 | biostudies-literature
| S-EPMC6849638 | biostudies-literature
| S-EPMC8954944 | biostudies-literature
| S-EPMC9226537 | biostudies-literature
| S-EPMC3517606 | biostudies-literature
| S-EPMC9146995 | biostudies-literature
| S-EPMC5503023 | biostudies-literature
| S-EPMC5435910 | biostudies-literature
| S-EPMC9981530 | biostudies-literature
| S-EPMC7713561 | biostudies-literature